Kasauli, Himachal Pradesh – In a significant step towards bolstering India’s public health infrastructure and national health security, Union Health Minister J.P. Nadda launched the indigenously manufactured tetanus and adult diphtheria (Td) vaccine on Saturday, February 21, 2026. The vaccine, produced at the Central Research Institute (CRI) in Kasauli, will now be included in the Universal Immunization Programme (UIP), making it more accessible to populations across the country.
The launch of the Td vaccine represents a key achievement in India’s growing capacity for domestic vaccine production. Minister Nadda described the event as “momentous,” emphasizing its importance in safeguarding public health. This development comes as India continues to strengthen its position as a leading global vaccine manufacturer, often referred to as the “pharmacy of the world.”
The CRI is poised to supply 55 lakh doses of the Td vaccine through the UIP by April of this year, with plans for progressive scaling up of production to meet future demand. This initiative builds upon the UIP, which currently provides 11 vaccines protecting against 12 vaccine-preventable diseases, and demonstrates a continued commitment to preventative healthcare.
A History of Vaccine Development and India’s Rapid Response
Highlighting the historical context of vaccine development, Minister Nadda noted the traditionally lengthy timelines associated with bringing new vaccines to market. He pointed to decades-long development processes for the tetanus vaccine, nearly 30 years for tuberculosis medicines, and a century of scientific effort for the Japanese Encephalitis vaccine. Although, he contrasted this with India’s recent success during the COVID-19 pandemic.
“In contrast, during the COVID-19 pandemic, India developed two indigenous vaccines within nine months and administered over 220 crore doses, including booster doses,” Nadda stated, underscoring the nation’s accelerated capabilities in vaccine research, development, and distribution. This rapid response showcased India’s scientific prowess and logistical efficiency on a global scale.
GMP Standards and Modernization of Public Sector Manufacturing
A crucial aspect of this achievement is that the CRI is the first government institute to manufacture vaccines under Good Manufacturing Practices (GMP) standards. This signifies a modernization and revitalization of public sector vaccine manufacturing units within India, ensuring the quality and reliability of domestically produced vaccines. Adherence to GMP standards is a critical component of international regulatory compliance and builds confidence in the safety and efficacy of the Td vaccine.
What is Tetanus and Diphtheria, and Why is Vaccination Important?
Tetanus and diphtheria are serious bacterial infections that can cause severe illness and even death. Tetanus, often called “lockjaw,” affects the nervous system, causing painful muscle contractions, particularly in the jaw and neck. Diphtheria causes a thick covering in the back of the throat, making it challenging to breathe and swallow. Both diseases are preventable through vaccination.
The Td vaccine is a booster vaccine, meaning it is given to maintain immunity against tetanus and diphtheria after initial childhood vaccinations. Boosters are essential because immunity from childhood vaccines can wane over time. Regular vaccination is particularly important for adults, especially those with wounds or who travel to areas where these diseases are prevalent.
Who Should Receive the Td Vaccine?
The Centers for Disease Control and Prevention (CDC) recommends that adults receive a Td or Tdap (tetanus, diphtheria, and pertussis) booster shot every 10 years. The CDC provides detailed information on tetanus and diphtheria vaccination recommendations, including specific guidance for travelers and individuals with certain medical conditions.
Looking Ahead: Strengthening India’s Immunization Program
The introduction of the indigenously manufactured Td vaccine into the UIP marks a significant milestone in India’s ongoing efforts to strengthen its immunization program and protect its citizens from preventable diseases. The CRI’s increased production capacity will play a vital role in ensuring a consistent supply of this essential vaccine. Further advancements in vaccine technology and manufacturing are expected to continue to enhance India’s self-reliance in public health.
The Ministry of Health and Family Welfare will continue to monitor the rollout of the Td vaccine and assess its impact on public health outcomes. Updates on the UIP and vaccine availability can be found on the ministry’s official website.
Disclaimer: This article provides general information about the tetanus and diphtheria vaccine and should not be considered medical advice. Please consult with a healthcare professional for personalized recommendations regarding vaccination.
What are your thoughts on India’s advancements in vaccine manufacturing? Share your comments below, and please share this article with your network.
Related reading
- Monash, Synchrotron Launch $2.9M HTX System for Accelerated Drug Development
- Ultrasound-Guided Fascia Iliaca Blocks Reduce Opioid Use in Hip Surgery
- India’s Education Minister Resigns: Victory for “Cockroach” Protests (archyde.com)
- Pakistan-Administered Kashmir Holds Viollent Election Amid India-Pakistan Tensions (newsy-today.com)
